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Abstract
The mitochondrial permeability transition is a widely studied, but poorly understood, phenomenon in mitochondrial bioenergetics. It
has been recognised that this phenomenon is related to the opening of a protein pore in the inner mitochondrial membrane, and that
opening of this pore is the cause of some forms of mitochondrial dysfunction. In this work, we propose that carvedilol, a multi-role
cardioprotective compound, may act as an inhibitor of the high-conductance state of the mitochondrial permeability transition pore, a
conclusion supported by the finding that carvedilol provides differential protection against mitochondrial swelling in sucrose and
KCl-based media, and that it is unable to protect against calcium-induced depolarisation of the mitochondrial membrane. We also show
that carvedilol inhibits the oxidation of mitochondrial thiol groups and that, beyond causing a slight depression of the membrane potential,
it has no inhibitory effect on mitochondrial calcium uptake.
A decrease in the number of oxidised protein thiol groups may be the main mechanism responsible for this selective inhibition of the
permeability transition pore in heart mitochondria. These effects may be important for the role of carvedilol in some cardiac pathologies.
q 2001 Elsevier Science B.V. All rights reserved.
1. Introduction
One pillar of the chemiosmotic theory of energy trans-
duction is the impermeability of the inner mitochondrial
membrane to solutes that are not transported by natural
mitochondrial carriers. This impermeability can be re-
versed by a phenomenon known as the ‘mitochondrial
 .permeability transition’ MPT , caused by the formation of
a proteinaceous pore the mitochondrial permeability tran-
.sition pore, MPTP , from several mitochondrial proteins
for reviews see Zoratti and Szabo, 1995; Vercesi et al.,`
.1997; Bernardi, 1999 . This sudden loss of membrane
integrity is perhaps the greatest riddle in mitochondrial
studies and is a controversial subject. Agents such as
 .calcium and phosphate the most studied , pro-oxidants
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such as t-butylhydroperoxide, or thiol cross-linkers such as
phenylarsine oxide are inducers of the MTP.
During events such as cardiac ischemiarreperfusion,
cardiac mitochondria may suffer severe damage due not
only to the increasing payload of oxidative injury but also
to the cellular and mitochondrial accumulation of calcium
and phosphate Baker et al., 1988, Kristian and Siesjo,´
.1996 . The role of the mitochondrial permeability transi-
tion pore in the reperfusion injury of the heart is well
established and may be a determinant of the fate of the
cell.
The physiology of the mitochondrial permeability tran-
sition pore has been described by some groups. The so-
called Alow-conductanceB state is useful for releasing the
calcium accumulated in the mitochondrial matrix and for
keeping the mitochondrial transmembrane electric poten-
 .tial DC within the normal range, avoiding membrane
hyperpolarisation Ichas et al., 1994, 1997; Ichas and
.Mazat, 1998 . The observed DC flickering in single mito-
chondria is considered to be due to repeated stochastic
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opening and closing of the mitochondrial permeability
 .transition pore Huser et al., 1998 . The transition to a
Ahigh-conductanceB state depends on the saturation of
calcium-binding sites and this state is also responsible for
a permanent ATP deficit, leading to cell necrosis Ichas
.and Mazat, 1998 .
 w  . x wCarvedilol 1– carbazolyl– 4 -oxy -3- 2-methoxyphe-
. x  .4.noxyethyl -amino -propanol- 2 is clinically used for the
treatment of congestive heart failure, mild to moderate
 .hypertension and myocardial infarction Dunn et al., 1997 .
Carvedilol competitively blocks b , b and a -adreno-1 2 1
ceptors, while displaying vasodilating properties. Its an-
tioxidant activity, which is responsible for additional car-
dioprotective actions not shared by other b-adrenoceptor
 .antagonists Yue et al., 1992a,b , has also been estab-
lished.
The effects of carvedilol in ischemic heart disease may
be due to the protection of mitochondrial function, for
instance, by suppression of oxidative damage to mitochon-
 .dria Moreno et al., 1998 or inhibition of the cardiac
 .exogenous NADH dehydrogenase Oliveira et al., 2000a ,
an organospecific enzyme located in the inner mitochon-
drial membrane that has been proposed to be a powerful
 .generator of the superoxide radical Nohl, 1987a,b .
Carvedilol also displays a weak protonophoretic activity
 .Oliveira et al., 2000b .
The aim of this study was to investigate the effects of
carvedilol in the mitochondrial permeability transition in-
duced by calciumrphosphate in rat heart mitochondria. To
this purpose, we followed several events associated with
the opening of the mitochondrial permeability transition
pore.
2. Materials and methods
2.1. Materials
Carvedilol and BM910228 were obtained from Boeh-
 .ringer Mannheim, Germany and prepared in dimethyl-
 .sulfoxide DMSO . All other compounds were purchased
 .from Sigma St. Louis, MO
2.2. Animals
 .Male Wistar rats 250–300 g , housed at 22q28C
under artificial light for 12-h lightrday cycle and with
access to water and food ad libitum, were used throughout
the experiments. The research reported here was carried
out in accordance with the National Requirement for Ver-
tebrate Animal Research.
2.3. Isolation of mitochondria from rat heart
Rat heart mitochondria from male Wistar rats 250–300
. g were prepared as previously described Oliveira et al.,
.2000a . Mitochondrial protein content was determined by
the biuret method, calibrated with bovine serum albumin.
2.4. Measurement of mitochondrial transmembrane poten-
tial
 .The mitochondrial transmembrane potential DC was
estimated with a TPPq electrode according to Kamo et al.
 .1979 without correction for the ApassiveB binding contri-
bution of TPPq to the mitochondrial membranes because
the purpose of the experiments was to show relative
changes in the potential rather than absolute values. A
matrix volume of 1.1 mlrmg. protein was assumed. Reac-
tions were carried out, at 258C, in 2 ml of the standard
media 200 mM sucrose, 10 mM Tris–Mops, 10 mM
. qEGTA, 5 mM KH PO supplemented with 3 mM TPP2 4
and 1 mg of mitochondria. Energised mitochondria were
obtained with 8 mM succinate plus 4 mM rotenone and
.0.5 mg oligomycin . Carvedilol was pre-incubated with the
mitochondrial suspension for 3 min before mitochondrial
energisation.
2.5. Determination of mitochondrial swelling
Changes in mitochondrial volume were followed by
monitoring the classic decrease in absorbance at 540 nm
with a Jasco V-560 spectrophotometer. The assays were
performed in 2 ml of standard media with 4 mM rotenone,
0.5 mg oligomycin and 8 mM succinate and 1 mg protein.
In a separate set of experiments, 200 mM sucrose was
replaced by 100 mM KCl or by a combination of either
100 mM polyethyleneglycol 200 or 1000 plus 60 mM KCl.
Carvedilol was pre-incubated with the mitochondrial
preparation for 3 min at 258C. In some experiments,
simultaneous measurements of mitochondrial DC and
swelling were obtained using a Spectronic 20 spectro-
photometer and a TPPq-selective electrode immersed in 4
ml of the standard media and with 2 mg of mitochondrial
protein.
2.6. Determination of mitochondria protein thiol content
To determine the antioxidant protective effect of
carvedilol on thiol groups in sucrose and KCl-based media,
 .we used a variation of Ellman’s method Riddles, 1979 .
After each incubation, two 0.75-ml samples were taken
and added to 0.75 ml of sulphosalicilic acid 4% each and
submitted to centrifugation at 15 500 g for 15 min in a
Sigma 3K30 Centrifuge at 48C.
The supernatant was discarded and the pellet was sus-
pended in 1.5 ml of phosphate buffer 100 mM, pH 8. The
suspension was sonicated and a 1.0-ml sample was diluted
to 2.6 ml in phosphate buffer medium containing 385 mM
dithionitrobenzoic acid. The absorption was measured at
412 nm.
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2.7. Calcium accumulation by heart mitochondria
The Ca2q storage capacity of mitochondria was esti-
mated spectrophotometrically at 660 nm in a Jasco 560
spectrophotometer, as described Solem and Wallace,
.1993 . Mitochondria were suspended at 0.25 mgrml in 2
ml of medium added to a cuvette maintained at 258C. After
2q  .1 min, Ca was added 200–300 nmol , and mitochon-
dria were energised with 10 mM succinate.
3. Results
The effect of increasing concentrations of carvedilol on
Ca2qrP -induced mitochondrial swelling was studied byi
measuring the changes in the suspension absorbance at 540
nm in a sucrose-based media. Carvedilol protected heart
mitochondria from the mitochondrial permeability transi-
 .tion in a dose-dependent manner Fig. 1 . Fig. 2 shows that
the addition of carvedilol to the mitochondrial suspension
affected the magnitude of swelling in a time-dependent
manner. Carvedilol, per se, neither stopped nor reversed
the mitochondrial permeability transition but needed at
least 3 min to have an inhibitory effect. To see whether
this protection extended to the usually observed membrane
depolarisation, we measured the variation in the mitochon-
 .drial electric potential DC after the addition of calcium
pulses. A representative recording is shown in Fig. 3,
where it can be seen that carvedilol did not have any
Fig. 1. Typical recording of mitochondrial swelling decrease of ab-
.  .sorbance at 540 nm induced by calcium 500 mM . Heart mitochondria
 .0.5 mgrml were incubated in 2 ml of media composed of 200 mM
sucrose, 10 mM Tris–Mops, 10 mM EGTA and 5 mM KH PO ,2 4
supplemented with 4 mM rotenone, 0.5 mg oligomycin and 8 mM
succinate. After a basal line was established, calcium was added. Where
referred, carvedilol was pre-incubated with mitochondria for 3 min at
 .  .258C. The additions were as follows: A 1 mM cyclosporin A, B 20
 .  .  .mM carvedilol, C 10 mM carvedilol, D 5 mM carvedilol and E no
additions.
Fig. 2. Effect of the time-lapse after carvedilol addition. Mitochondria
 .were incubated as described in the legend of Fig. 1. Carvedilol 20 mM
 .was added at different times A, B and C . The letters at the ends of
 .curves correspond to the times of addition. D No additions. The
recording is representative.
protective effect against calcium-induced depolarisation,
whatever the concentration. Simultaneous recording of
mitochondrial DC and swelling showed that although
there was an inhibitory effect on mitochondrial swelling,
 .no difference was observed in the DC data not shown .
This led us to propose that carvedilol caused a selective
inhibition of the Ahigh-conductanceB state of the mitochon-
drial permeability transition pore. Sucrose, but not proton,
influx would be prevented by carvedilol, with consequent
membrane depolarisation.
This hypothesis was further corroborated by the mea-
surement of mitochondrial swelling in a KCl-based media.
Fig. 3. Mitochondrial electric potential measurements obtained with a
q  .TPP -selective electrode. Calcium 500 mM was added in order to
induce the mitochondrial permeability transition pore, under the same
conditions as described in the legend of Fig. 1 media supplemented with
q .  .3 mM TPP . Carvedilol 10 and 20 mM was pre-incubated for 3 min
with heart mitochondria. Individual calibrations with valinomycin were
made for each of the experiments to set the baseline. The recordings are
representative of five different preparations.
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Fig. 4. Different levels of protection afforded by 20 mM carvedilol
 .against mitochondrial swelling decrease of absorbance at 540 nm
induced by 600 mM calcium in a sucrose 200 mM sucrose, 10 mM
Tris–Mops, 10 mM EGTA and 5 mM KH PO , plus 4 mM rotenone, 0.52 4
. mg oligomycin and 8 mM succinate, left recording or KCl-based 100
mM KCl, 10 mM Tris–Mops, 10 mM EGTA and 5 mM KH PO ,2 4
supplemented with 4 mM rotenone, 0.5 mg oligomycin and 8 mM
.succinate, right recording medium. Carvedilol was pre-incubated with
mitochondria for 3 min.
We found out that 20 mM carvedilol had no effect on the
 .magnitude of swelling Fig. 4, right , which contrasts
sharply with the effect of the same concentration of
carvedilol in a sucrose-based media, where an inhibition is
 .clearly visible Fig. 4, left . Carvedilol even increased the
rate of swelling in KCl-based media. This would mean that
the entry of the larger molecule, sucrose, was restricted, in
contrast to the entry of much smaller ions. In other words,
carvedilol caused a selective exclusion of solutes. When
media based on polyethyleneglycols with molecular
weights 200 and 1000 were used, and despite an overall
inhibitory effect against mitochondrial swelling, we no-
ticed that the inhibition was more pronounced in the
 .polyethyleneglycol -based media data not shown .1000
Fig. 5. Oxidation of mitochondrial protein thiol groups determined as
described in Section 2. Mitochondria were incubated with calcium 500
.  .mM for 3 min before the assays Ca and CV . When present, carvedilol
 .CV was pre-incubated with mitochondria for 30 min before calcium
addition. Media were the same as described in the legend of Fig. 1.
Results are means"S.E.M. of four different preparations. ) p-0.001,
compared with control, ) ) p-0.05, compared with calcium without
carvedilol.
The oxidation of protein thiol groups is known to be
one of the hallmarks of induction of the mitochondrial
permeability transition. We determined the extent of
carvedilol-induced protection against protein thiol group
oxidation. We found out that carvedilol decreased the
extent of protein thiol group oxidation induced by Ca2qrP .i
Fig. 5 shows the extent of protection in the sucrose-based
media. The results in KCl-based media were very similar
 .data not shown .
Measurements of calcium movements, using Arsenazo
as a calcium sensitive probe, showed that carvedilol had a
dual action on mitochondrial calcium accumulation: a neg-
ligible effect when calcium concentrations were below the
threshold for pore opening i.e., calcium uptake was nor-
.  .mal Fig. 6, down and a protective effect when the
calcium concentration was enough to cause pore activation
 .Fig. 6, up . Thus, carvedilol increased the rate and extent
of calcium accumulation at high calcium concentrations,
demonstrating a protective effect, while not having any
effect on calcium uptake at low calcium concentrations.
These results showed that the decrease in mitochondrial
DC was not enough to decrease calcium entry.
Fig. 6. Determination of extra-mitochondrial calcium movements using
Arsenazo as a calcium-sensitive probe. Two millilitres of assay medium
200 mM sucrose, 10 mM EGTA–Tris, 5 mM KH PO , 10 mM Tris, pH2 4
. 2q7.4 was supplemented just before the Ca capacity assays with 100
mM of Arsenazo III, 2 mM rotenone and 1 mgrml oligomycin. Mito-
chondria were suspended at 0.25 mgrml. After 1 min of incubation,
2q Ca was added 300 nmol—upper recording, 200 nmol—lower record-
.ing , and mitochondria were energised with 10 mM succinate. Carvedilol
10 mM was used with a 3-min previous incubation. Recordings are
representative.
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4. Discussion
In this work, we studied the effect of carvedilol on the
permeability transition in heart mitochondria, a deleterious
event often associated with mitochondrial and cellular
dysfunction.
As cardiac cells handle high concentrations of calcium,
heart mitochondria are much more resistant to calcium
than liver mitochondria, for example. In our work, it was
necessary to use 5 mM P and 500 mM calcium or higheri
to induce mitochondrial swelling and depolarisation. In
liver mitochondria, the calcium concentrations used to
induce mitochondrial permeability transition pore opening
are usually five times lower. As cardiomyocytes need a
constant supply of mitochondrial ATP to ensure their
functions, their survival is threatened when mitochondrial
dysfunction occurs. In a condition of ischemiarreperfu-
sion, where there is increased oxidative stress, calcium and
P , the mitochondrial permeability transition occursi
Crompton and Costi, 1990; Halestrap et al., 1998; Baker
.et al., 1988; Kristian and Siesjo, 1996 . The use of drugs to´
protect cardiac cells from the mitochondrial permeability
transition is most valuable in these situations.
In this work, we showed that carvedilol is an inhibitor
of the mitochondrial permeability transition, exerting a
dose-dependent effect against mitochondrial swelling Fig.
.1 . The specific inhibitor of the mitochondrial permeability
transition pore, the immunosuppressive peptide cyclos-
porin A, completely abolished mitochondrial swelling, as
 .expected Broekemeier et al., 1989 . The protective effect
 .of carvedilol was time-dependent Fig. 2 because it took
up to 3 min to attain the maximum inhibitory effect. This
lag time may correspond to the insertion of carvedilol into
the mitochondrial membrane because carvedilol has a great
 .tendency to insert into membranes Cheng et al., 1996 .
The opening of the mitochondrial permeability transition
pore occurred simultaneously with mitochondrial depolari-
 .sation drop in DC . No protective effect of carvedilol
against Ca2q-induced depolarisation was observed when a
TPPq-selective electrode was used. As seen in Fig. 3,
carvedilol was unable to maintain DC after a strong Ca2q
pulse. The only visible effect was a slight decrease in DC ,
concomitant with a weak protonophoretic activity Oliveira
.et al., 2000b . This was confirmed by results obtained with
simultaneous recordings of mitochondrial DC and
swelling, where inhibition was noticed in the swelling
component but not in the DC depolarisation component.
Carvedilol was unable to inhibit mitochondrial swelling
 .in a KCl-based media Fig. 4 but showed a stronger
inhibitory effect in a polyethyleneglycol -based media1000
than in a polyethyleneglicol -based media. This may200
mean that carvedilol only inhibited one of the substrates of
the mitochondrial permeability transition pore, the high-
conductance state, which is responsible for mitochondrial
swelling in sucrose-based media. In other words, carvedilol
probably inhibited the entry of large molecules into the
mitochondrial matrix but had no effect on the entry of
smaller molecules. In our opinion, this is the reason why
we observed different degrees of protection induced by
carvedilol according to the size of the external osmotically
active molecules.
Carvedilol also inhibited the oxidation of mitochondrial
 .protein thiol groups Fig. 5 , an event associated with
opening of the mitochondrial permeability transition pore.
 .As proposed by Zago et al. 2000 , the redox state of
endogenous pyridine nucleotides and hence the redox state
of mitochondrial thiols can determine the solute selectivity
of the permeability transition pore. This may explain the
different degrees of protection provided by carvedilol in
sucrose and in KCl-based media, in spite of the observed
similarity in inhibition of protein thiol group oxidation.
The decrease in thiol group oxidation can be explained by
the antioxidant activity of carvedilol Yue et al., 1992a,b;
.Moreno et al., 1998 . This agrees with results obtained
 w  . x wwith BM910228 1- 3-hydroxy-carbazolyl- 4 -oxy -3- 2-
. x  .4.methoxyphenoxyethyl -amino -propanol- 2 , a hydroxy-
lated metabolite of carvedilol, that has greater antioxidant
 .activity Yue et al., 1994 , which inhibited mitochondrial
swelling in the sucrose-media to a greater extent than did
 .carvedilol in the same concentrations data not shown .
Protection against thiol group oxidation may be the
main mechanism by which carvedilol inhibits the mito-
chondrial permeability transition pore in its high conduc-
tance state. We also considered that carvedilol, due to its
protonophoretic properties, might depress calcium influx
into the mitochondria, thus inhibiting the permeability
transition in an indirect form. Our results with the Arse-
nazo technique ruled out this hypothesis. Carvedilol not
only did not have an inhibitory effect on calcium influx at
 .low calcium loads Fig. 6, down but it also inhibited
mitochondrial calcium release induced by high calcium
 .loads Fig. 6, up .
On the basis of our results, we propose that carvedilol
may act as a selective inhibitor of the high-conductance
state of the mitochondrial permeability transition pore, as
described previously Ichas et al., 1994, 1997; Ichas and
. Mazat, 1998 , or, as proposed in some models Petronilli et
.al., 1999 , as an inhibitor of the long lasting pore opening
responsible for the observed extensive swelling in the
sucrose-based media.
Since the low-conductance state of the mitochondrial
permeability transition pore has been associated with pro-
tective mechanisms against calcium overload, oxidative
stress and DC hyperpolarisation Ichas and Mazat, 1998;
.Huser and Blatter, 1999 , it is possible that the cardiopro-
tective action of carvedilol is, partly, due to a selective
inhibition of a deleterious high-conductance state of the
mitochondrial permeability transition pore, without inhibit-
ing the low-conductance state of the pore, which is consid-
ered to have physiological functions. Work is underway in
our laboratory to determine the precise mechanism of
carvedilol actions and to identify the components of the
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mitochondrial permeability transition event. This is very
important in order to explain some results that appeared in
the literature concerning non-conventional, mitochondrial
permeability transitions Sokolove and Haley, 1996;
.Kushnareva and Sokolove, 2000 . In the future, we are
also interested in finding out whether carvedilol actually
binds to a mitochondrial protein that forms the pore.
In conclusion, we propose that carvedilol is an inhibitor
of the high-conductance state of the mitochondrial perme-
ability transition pore, acting on mitochondrial swelling
and calcium efflux without preventing DC depolarisation
or swelling in a ionic media. With regard to the clinical
relevance of the finding, although carvedilol is not able to
prevent mitochondrial DC depolarisation, it might prevent
structural damage to the mitochondria. The antioxidant
activity of carvedilol may help prevent the irreversible
mitochondrial dysfunction caused by the permeability tran-
sition.
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